Highlights of the ESH-iCMLf 26th Annual John Goldman Conference

Clinical Highlights

Expert

Professor Jorge Cortes
Georgia Cancer Centre
Augusta, USA

00:00 Welcome & Introduction
01:36 Clinical Hilights - Jorge Cortes
02:35 Highest Scoring Abstracts
12:16 Propensity score analysis of Ponatinib versus Asciminib
15:25 Reports on newer TKI's

Biological Highlights

Expert

Professor Daniela Krause
Director of the Institute of Transfusion Medicine,
University of Mainz
Mainz, Germany

00:00 Introduction
01:54 Resistance
11:04 Blast Crisis
13:54 New concepts and new developments
19:37 Q&A Session
20:15 Question 1 - Treating patients resistant to third-line (or more) treatment if BMT is not available
22:24 Question 2 - What is the criteria for Ruxalitinib, JAK2 -positive, and or other mutations? 
23:58 Question 3 - We see many new TKIs in the pipeline, but where do we stand when talking about finding an actual definitive cure for CML? What is the hottest target for today? 
26:45 Question 4 - With the blast crisis study with ponatinib plus AZA, did it include transplant eligible patients? And if so, how many were transplanted? 
28:24 Question 5 - Daniela, could you outline one particular area of research that you think is the most promising coming forward in regards to clinical need? 
29:41 Question 6 - And Jorge, what particularly stood out for you in the biology sessions that you thought would be coming through for clinical use in the near future? 
32:05 Thanks